Email Alerts

Nuvectis Pharma

Precision Medicine for the Treatment of
Complement Related Diseases and Cancer

Explore our pipeline Investor Relations

Innovative precision medicine for the treatment of complement-related conditions and oncology

Nuvectis Pharma (Nasdaq: NVCT) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. Our lead candidate is ciprocopan, a Factor B inhibitor for once daily oral administrations, with best-in-class potential, approved in China in July 2026 for treatment of PNH in patients previously untreated with complement inhibitors. Our oncology pipeline includes NXP200 (paradox breaking, BRAF kinase inhibitor) and NXP900 (YES1/SRC kinase inhibitor) for the treatment of advanced cancers.

PipelineOur complement and oncology programs, from mechanism to clinic.Learn more LeadershipMeet the management team and board of directors.Learn more Investor RelationsStock information, filings, events and presentations.Learn more

Pipeline

Our programs

ComplementNXP100Complement Factor B InhibitorNXP100 is a small molecule for oral, once daily administration that inhibits Factor B, a critical protease within the alternative pathway of the complement cascade.View program OncologyNXP200Paradox Breaker BRAF InhibitorNXP200 is an oral small-molecule, paradox breaker BRAF inhibitor.View program OncologyNXP900SRC/YES1 Kinase InhibitorNXP900 is an oral small-molecule inhibitor targeting the SRC Family of Kinases (SFKs), with low nanomolar potency for SRC and YES1.View program

News

Latest Press Releases

View all press releases
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026Read more Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade GliomaRead more Nuvectis Pharma To Participate in Upcoming Investor ConferencesRead more Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business HighlightsRead more Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsRead more Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement InhibitorsRead more Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common StockRead more Nuvectis Pharma Announces Proposed Public Offering of Common StockRead more

Email Alerts

Stay informed

Get Nuvectis press releases and SEC filings delivered to your inbox.

Alert Types